system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, METHODS, METHODS, RESULTS. Meshes: Anticholesteremic Agents, Aryldialkylphosphatase, Atorvastatin, Carboxylic Ester Hydrolases, Cholesterol, HDL, Double-Blind Method, Female, Genotype, Heptanoic Acids, Humans, Hyperlipoproteinemia Type II, Male, Middle Aged, Polymorphism, Genetic, Pyrroles, Simvastatin, Treatment Outcome.
user
Is the effect of statin therapy on plasma high-density lipoprotein cholesterol levels modified by paraoxonase-1 in patients with familial hypercholesterolaemia? Context: Statins reduce low-density lipoprotein cholesterol (LDL-C) and can raise high-density lipoprotein cholesterol (HDL-C). HDL-bound paraoxonase-1 (PON1) is associated with variations in plasma HDL-C, and may, therefore, contribute to changes of HDL-C during statin therapy. The effects of baseline PON1 status to HDL-C changes because of statin therapy were investigated. PON1 status was determined with (i) PON1 -107C>T and 192Q>R genotype, (ii) PON1 levels and (iii) PON1 paraoxonase, diazoxonase and arylesterase activity. Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands. A total of 134 familial hypercholesterolaemia (FH) patients undergoing atorvastatin or simvastatin therapy. PON1 levels and activities significantly modified the HDL-C increment (P=0.002 for PON1 levels and arylesterase activity and P=0.001 for diazoxonase activity). The effects were even more evident amongst subgroup classifications based on PON1 status and baseline HDL-C concentrations: the HDL-C increment was more pronounced in subgroups of -107CT/TT or 192QR/RR genotype combined with low baseline HDL-C (+13.9%, P<0.001, respectively+15.4%, P<0.001). In contrast, the -107CC or 192QQ genotype in combination with high baseline HDL-C, did not show a significant increase of HDL-C.
assistant
PON1 status in conjunction with baseline HDL-C levels predicts HDL-C increment during statin therapy in FH patients. Final Decision: yes